

AMENDMENT

In the Specification:

Please amend the specification as follows:

Beginning on page 6, spanning lines 16-20, please replace with the following:

~~FIG. 5~~FIG. 4: *N*-Terminal vs. *C*-Terminal anchoring strategy comparison. (A) Anti-digoxigenin Dig scfv, anti-PA M18 scFv and anti-methamphetamine Meth scFv expressed as *N*-terminal fusions in the pAPEx1 vector in *E. coli* specifically label with 200nM of their respective antigen. (B) *C*-terminal fusions of same scFv in pAK200 vector specifically labeled with 200nM of their respective antigen.

Beginning on page 6, spanning lines 21-22, please replace with the following:

~~FIG. 6~~FIG. 5: View from the top of the antibody binding pocket showing the conformation and amino acid substitutions in the 1H, M5, M6 and M18 sequences.

Beginning on page 6, spanning lines 23-25, please replace with the following:

~~FIG. 7~~FIG. 6: Alignment of 14B7 scFv (SEQ ID NO:21) and M18 scFv (SEQ ID NO:23) sequences showing variable heavy and variable light chains and mutations made to improve binding affinity.